v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Research and development $ 20,320 $ 12,542
Research and development - related party 150 150
General and administrative 1,969 3,432
Total operating expenses 22,439 16,124
Loss from operations (22,439) (16,124)
Other income, net 676 468
Net loss before taxes (21,763) (15,656)
Income tax expense (373) 0
Net loss $ (22,136) $ (15,656)
Net loss per share - basic $ (1.24) $ (1.37)
Net loss per share - diluted $ (1.24) $ (1.37)
Weighted average shares and pre-funded warrants outstanding, basic 17,837,406 11,398,971
Weighted average shares and pre-funded warrants outstanding, diluted 17,837,406 11,398,971
Comprehensive Loss:    
Net loss $ (22,136) $ (15,656)
Unrealized loss on available-for-sale securities, net (7) (11)
Comprehensive loss $ (22,143) $ (15,667)